For research use only. Not for therapeutic Use.
Cethromycin（Cat No.:I005965）is a macrolide antibiotic with potent activity against Gram-positive and some Gram-negative bacteria, showing promise in treating respiratory infections. Known for its broad-spectrum efficacy, it is particularly valuable against resistant strains of Streptococcus pneumoniae and Haemophilus influenzae. Cethromycin’s unique mechanism, involving binding to the bacterial ribosome, inhibits protein synthesis, leading to effective bacterial eradication. Its pharmacokinetic profile allows for good oral bioavailability, making it a convenient option in clinical settings. Cethromycin is being studied for its potential in treating bioterrorism-related pathogens, adding to its clinical importance.
| Catalog Number | I005965 |
| CAS Number | 205110-48-1 |
| Synonyms | Cethromycin; ABT-773; ABT 773; ABT773; A-195773; A 195773; A195773;(3aS,4R,7R,9R,10R,11R,13R,15R,15aR)-10-(((2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)-4-ethyl-3a,7,9,11,13,15-hexamethyl-11-(((E)-3-(quinolin-3-yl)a |
| Molecular Formula | C42H59N3O10 |
| Purity | ≥95% |
| Target | Bacterial |
| Solubility | Soluble in DMSO |
| Storage | Store at -20°C |
| IUPAC Name | (1S,2R,5R,7R,8R,9R,11R,13R,14R)-8-[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-2-ethyl-1,5,7,9,11,13-hexamethyl-9-[(E)-3-quinolin-3-ylprop-2-enoxy]-3,17-dioxa-15-azabicyclo[12.3.0]heptadecane-4,6,12,16-tetrone |
| InChI | InChI=1S/C42H59N3O10/c1-11-32-42(8)36(44-40(50)55-42)25(4)33(46)23(2)21-41(7,51-18-14-15-28-20-29-16-12-13-17-30(29)43-22-28)37(26(5)34(47)27(6)38(49)53-32)54-39-35(48)31(45(9)10)19-24(3)52-39/h12-17,20,22-27,31-32,35-37,39,48H,11,18-19,21H2,1-10H3,(H,44,50)/b15-14+/t23-,24-,25+,26+,27-,31+,32-,35-,36-,37-,39+,41-,42-/m1/s1 |
| InChIKey | PENDGIOBPJLVBT-ONLVEXIXSA-N |
| SMILES | CC[C@@H]1[C@@]2([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H](C(=O)[C@H](C(=O)O1)C)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)OC/C=C/C4=CC5=CC=CC=C5N=C4)C)C)NC(=O)O2)C |
| Reference | </br>1:Inducible expression of erm(B) by the ketolides telithromycin and cethromycin. Park B, Min YH.Int J Antimicrob Agents. 2015 Aug;46(2):226-7. doi: 10.1016/j.ijantimicag.2015.05.001. Epub 2015 Jun 3. No abstract available. PMID: 26088553 </br>2:Introduction of a nitrogen-containing side chain appended on C-10 of cethromycin leads to reduced CYP3A4 inhibition (WO2014049356A1). Liang JH.Expert Opin Ther Pat. 2015 Jan;25(1):119-23. doi: 10.1517/13543776.2014.971754. Epub 2014 Oct 18. Review. PMID: 25327846 </br>3:Desmethyl Macrolides: Synthesis and Evaluation of 4,8,10-Tridesmethyl Cethromycin. Wagh B, Paul T, Debrosse C, Klepacki D, Small MC, Mackerell AD Jr, Andrade RB.ACS Med Chem Lett. 2013 Nov 14;4(11):1114-1118. PMID: 24470840 Free PMC Article</br>4:Cethromycin: a new ketolide antibiotic. Mansour H, Chahine EB, Karaoui LR, El-Lababidi RM.Ann Pharmacother. 2013 Mar;47(3):368-79. doi: 10.1345/aph.1R435. Epub 2013 Mar 5. Review. PMID: 23463743 </br>5:Cethromycin versus clarithromycin for community-acquired pneumonia: comparative efficacy and safety outcomes from two double-blinded, randomized, parallel-group, multicenter, multinational noninferiority studies. English ML, Fredericks CE, Milanesio NA, Rohowsky N, Xu ZQ, Jenta TR, Flavin MT, Eiznhamer DA.Antimicrob Agents Chemother. 2012 Apr;56(4):2037-47. doi: 10.1128/AAC.05596-11. Epub 2012 Jan 30. PMID: 22290969 Free PMC Article</br>6:Cethromycin-mediated protection against the plague pathogen Yersinia pestis in a rat model of infection and comparison with levofloxacin. Rosenzweig JA, Brackman SM, Kirtley ML, Sha J, Erova TE, Yeager LA, Peterson JW, Xu ZQ, Chopra AK.Antimicrob Agents Chemother. 2011 Nov;55(11):5034-42. doi: 10.1128/AAC.00632-11. Epub 2011 Aug 22. PMID: 21859946 Free PMC Article</br>7:In vitro activity of cethromycin against Burkholderia pseudomallei and investigation of mechanism of resistance. Mima T, Schweizer HP, Xu ZQ.J Antimicrob Chemother. 2011 Jan;66(1):73-8. doi: 10.1093/jac/dkq391. Epub 2010 Oct 21. PMID: 20965890 Free PMC Article</br>8:Cethromycin: a promising new ketolide antibiotic for respiratory infections. Rafie S, MacDougall C, James CL.Pharmacotherapy. 2010 Mar;30(3):290-303. doi: 10.1592/phco.30.3.290. Review. PMID: 20180612 </br>9:In vitro activity of ceftaroline, ceftobiprole and cethromycin against clinical isolates of Streptococcus pneumoniae collected from across Canada between 2003 and 2008. Patel SN, Pillai DR, Pong-Porter S, McGeer A, Green K, Low DE.J Antimicrob Chemother. 2009 Sep;64(3):659-60. doi: 10.1093/jac/dkp231. Epub 2009 Jul 3. No abstract available. PMID: 19578080 </br>10:In vitro activity of the investigational ketolide cethromycin against macrolide- and penicillin-resistant Streptococcus pneumoniae: review of the 1998 to 2006 Canadian Respiratory Organism Susceptibility Study (CROSS). Wierzbowski AK, Karlowsky JA, Hoban DJ, Zhanel GG.J Antimicrob Chemother. 2009 Mar;63(3):620-2. doi: 10.1093/jac/dkn532. Epub 2009 Jan 16. No abstract available. PMID: 19151038 |
